NOUV Stock Overview
Nouveau Life Pharmaceuticals, Inc. es una empresa en fase de desarrollo dedicada a la elaboración de productos nutracéuticos.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Nouveau Life Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0002 |
| 52 Week High | US$0.0003 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -33.33% |
| 1 Year Change | -33.33% |
| 3 Year Change | -66.67% |
| 5 Year Change | -66.67% |
| Change since IPO | -99.94% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| NOUV | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.7% | -2.1% |
| 1Y | -33.3% | 15.5% | 24.7% |
Rentabilidad frente al sector: NOUV obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del 23.6%.
Rentabilidad vs. Mercado: NOUV obtuvo unos resultados inferiores a los del mercado US, que fue del 30.4% el año pasado.
Price Volatility
| NOUV volatility | |
|---|---|
| NOUV Average Weekly Movement | 53.1% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: NOUVha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: NOUV(59%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de los valores de US.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Brian Shibley |
Nouveau Life Pharmaceuticals, Inc, empresa en fase de desarrollo, se dedica al desarrollo de productos nutracéuticos. Ofrece alternativas naturales y medicamentos con receta. La empresa era conocida anteriormente como Hybrid Fuels, Inc. y cambió su nombre a Nouveau Life Pharmaceuticals, Inc. en mayo de 2012.
Nouveau Life Pharmaceuticals, Inc. Fundamentals Summary
| NOUV fundamental statistics | |
|---|---|
| Market cap | US$2.15m |
| Earnings (TTM) | -US$503.31k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs NOUV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOUV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$503.32k |
| Earnings | -US$503.31k |
Last Reported Earnings
Mar 31, 2008
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did NOUV perform over the long term?
See historical performance and comparison